Kotak Healthcare Fund Regular Growth

Fund Overview

Fund Size

₹416 Cr

Expense Ratio

2.39%

ISIN

INF174KA1PW4

Minimum SIP

₹100

Exit Load

No Charges

Inception Date

11 Dec 2023

About this fund

Kotak Healthcare Fund Regular Growth is a Sector - Healthcare mutual fund schemes offered by Kotak Mahindra Mutual Fund. This fund has been in existence for 1 years, 2 months and 11 days, having been launched on 11-Dec-23.
As of 21-Feb-25, it has a Net Asset Value (NAV) of ₹12.18, Assets Under Management (AUM) of 415.85 Crores, and an expense ratio of 2.39%.

Kotak Healthcare Fund Regular Growth has given a CAGR return of 17.91% since inception.
The fund's asset allocation comprises around 98.24% in equities, 0.00% in debts, and 1.76% in cash & cash equivalents.
You can start investing in Kotak Healthcare Fund Regular Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+6.69%

+12.48% (Cat Avg.)

Since Inception

+17.91%

— (Cat Avg.)

Portfolio Summaryas of 31st January 2025

Equity	₹408.54 Cr	98.24%
Others	₹7.32 Cr	1.76%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹66.27 Cr	15.94%
Cipla Ltd	Equity	₹25.45 Cr	6.12%
Divi's Laboratories Ltd	Equity	₹20.08 Cr	4.83%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹17.72 Cr	4.26%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹16.76 Cr	4.03%
Torrent Pharmaceuticals Ltd	Equity	₹16.02 Cr	3.85%
Dr Reddy's Laboratories Ltd	Equity	₹15.22 Cr	3.66%
Lupin Ltd	Equity	₹14.98 Cr	3.60%
Aurobindo Pharma Ltd	Equity	₹14.18 Cr	3.41%
Orchid Pharma Ltd	Equity	₹14.13 Cr	3.40%
Jubilant Pharmova Ltd	Equity	₹13.64 Cr	3.28%
Apollo Hospitals Enterprise Ltd	Equity	₹13.62 Cr	3.28%
Alkem Laboratories Ltd	Equity	₹12.15 Cr	2.92%
Sai Life Sciences Ltd	Equity	₹11.56 Cr	2.78%
Zydus Lifesciences Ltd	Equity	₹11.16 Cr	2.68%
Glenmark Pharmaceuticals Ltd	Equity	₹10.9 Cr	2.62%
Ami Organics Ltd	Equity	₹10.73 Cr	2.58%
Ajanta Pharma Ltd	Equity	₹10.61 Cr	2.55%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹10.57 Cr	2.54%
Laxmi Dental Ltd	Equity	₹10.06 Cr	2.42%
Krishna Institute of Medical Sciences Ltd	Equity	₹9.14 Cr	2.20%
Krsnaa Diagnostics Ltd	Equity	₹8.45 Cr	2.03%
Triparty Repo	Cash - Repurchase Agreement	₹8.1 Cr	1.95%
Fortis Healthcare Ltd	Equity	₹7.68 Cr	1.85%
Hikal Ltd	Equity	₹7.45 Cr	1.79%
Yatharth Hospital and Trauma Care Services Ltd	Equity	₹7.17 Cr	1.72%
Innova Captab Ltd	Equity	₹6.36 Cr	1.53%
Emcure Pharmaceuticals Ltd	Equity	₹6.03 Cr	1.45%
Marksans Pharma Ltd	Equity	₹6.03 Cr	1.45%
Biocon Ltd	Equity	₹4.35 Cr	1.05%
Alembic Pharmaceuticals Ltd	Equity	₹3.88 Cr	0.93%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹3.76 Cr	0.90%
Mankind Pharma Ltd	Equity	₹2.44 Cr	0.59%
Net Current Assets/(Liabilities)	Cash	₹-0.78 Cr	0.19%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹397.8 Cr	95.66%
Basic Materials	₹10.73 Cr	2.58%

Risk & Performance Ratios

Fund Managers

Abhishek Bisen

Since December 2023

Shibani Kurian

Since December 2023

Dhananjay Tikariha

Since March 2024

Additional Scheme Detailsas of 31st January 2025

ISIN

INF174KA1PW4

Expense Ratio

2.39%

Exit Load

No Charges

Fund Size

₹416 Cr

Age

1 year 2 months

Lumpsum Minimum

₹100

Fund Status

Open Ended Investment Company

Benchmark

Nifty Healthcare Index PR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹27.99 Cr	11.6%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.1%	1.0%	₹815.09 Cr	6.3%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹815.09 Cr	4.8%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹41.19 Cr	9.0%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹216.51 Cr	11.9%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹216.51 Cr	9.8%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹2652.24 Cr	12.3%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2652.24 Cr	10.7%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹866.14 Cr	8.2%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹18.92 Cr	8.9%

About the AMC

Kotak Mahindra Mutual Fund

+91 22 61152100

https://www.kotakmf.com/

Total AUM

₹5,12,837 Cr

Address

2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051

Other Funds by Kotak Mahindra Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Kotak FMP Series 327 Direct Growth Moderately High risk	-	0.0%	₹206.03 Cr	-
Kotak FMP Series 326 - 175 Days Direct Growth Moderate Risk	-	-	-	-
Kotak FMP Series 325 - 90 Days Direct Growth Moderate Risk	-	0.0%	-	-
Kotak FMP Series 324 - 109 Days Direct Growth Moderately High risk	-	0.0%	-	-
Kotak Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹415.85 Cr	8.5%
Kotak FMP Series 323 Direct Growth Low Risk	-	0.0%	-	-
Kotak Consumption Fund Direct Growth Very High Risk	0.6%	0.0%	₹1231.06 Cr	16.5%
Kotak Nifty G-Sec July 2033 Index Fund Direct Growth Moderate Risk	0.1%	0.0%	₹19.46 Cr	8.7%
Kotak Multi Asset Allocation Fund Direct Growth High Risk	0.4%	1.0%	₹7680.06 Cr	9.7%
Kotak S&P BSE Housing Index Fund Direct Growth Very High Risk	0.2%	0.0%	₹17.59 Cr	2.9%
Kotak Fixed Maturity Plan 1174 Days Series 268 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 308 - 1125 Days Direct Growth Moderately High risk	-	0.0%	₹94.00 Cr	8.6%
Kotak Yearly Interval Plan Series 1 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak Fixed Maturity Plan 1355 Days Series 286 Direct Growth Low to Moderate Risk	-	-	-	-
Kotak FMP Series 304 Direct Growth Moderate Risk	-	-	₹109.38 Cr	9.1%
Kotak Fixed Maturity Plan Series 262 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 291 - 1826 Days Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak Fixed Maturity Plan Series 264 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 310 - 1131 Days Direct Growth Moderate Risk	-	0.0%	₹125.59 Cr	7.7%
Kotak FMP Series 306 Direct Growth Moderate Risk	-	0.0%	-	-
Kotak Quarterly Interval Series 12 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak Fixed Maturity Plan Series 249 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 295 Direct Growth Moderate Risk	-	0.0%	-	-
Kotak Fixed Maturity Plan Series 258 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 298 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 290 - 1180 Days Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak Monthly Interval Series 4 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 293 - 1826 Days Direct Growth Moderate Risk	-	0.0%	-	-
Kotak India Growth Fund Series IV Direct Growth Very High Risk	0.3%	0.0%	₹132.94 Cr	50.2%
Kotak Fixed Maturity Plan Series 260 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 287 - 1188 days Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak Fixed Maturity Plan Series 272 Direct Growth Low to Moderate Risk	-	-	-	-
Kotak Fixed Maturity Plan Series 273 Direct Growth Low to Moderate Risk	-	-	-	-
Kotak FMP Series 305 Direct Growth Low to Moderate Risk	-	0.0%	₹33.56 Cr	7.6%
Kotak FMP Series 300 - 1223 days Direct Growth Low to Moderate Risk	-	0.0%	₹241.41 Cr	7.7%
Kotak Quarterly Interval Series 13 Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 292 - 1735 Days Direct Growth Low to Moderate Risk	-	0.0%	₹447.13 Cr	8.0%
Kotak FMP Series 289 -1179 days Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak FMP Series 288 -1177 days Direct Growth Low to Moderate Risk	-	0.0%	-	-
Kotak Small Cap Fund Direct Growth Very High Risk	0.6%	1.0%	₹16450.27 Cr	5.8%
Kotak Flexicap Fund Direct Growth Very High Risk	0.7%	1.0%	₹49112.04 Cr	7.9%
Kotak Equity Opportunities Fund Direct Growth Very High Risk	0.6%	1.0%	₹24533.81 Cr	8.2%
Kotak Taxsaver Fund Direct Growth Very High Risk	0.7%	0.0%	₹5892.76 Cr	4.9%
Kotak Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹372.49 Cr	-4.4%
Kotak Nifty 50 Index Fund Direct Growth Very High Risk	0.1%	0.0%	₹742.20 Cr	4.1%
Kotak Infrastructure and Economic Reform Fund Direct Growth Very High Risk	0.7%	0.0%	₹2251.13 Cr	3.2%
Kotak Low Duration Fund Direct Growth Moderate Risk	0.4%	0.0%	₹11882.66 Cr	8.1%
Kotak Bluechip Fund Direct Growth Very High Risk	0.6%	1.0%	₹9267.66 Cr	7.5%
Kotak Bond Fund Direct Growth Moderate Risk	0.7%	0.0%	₹2087.67 Cr	8.1%
Kotak Bond Fund Short Term Plan Direct Growth Low to Moderate Risk	0.4%	0.0%	₹16979.34 Cr	8.3%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of Kotak Healthcare Fund Regular Growth?

The NAV of Kotak Healthcare Fund Regular Growth, as of 21-Feb-2025, is ₹12.18.

What is the portfolio composition of Kotak Healthcare Fund Regular Growth?

The fund's allocation of assets is distributed as 98.24% in equities, 0.00% in bonds, and 1.76% in cash and cash equivalents.

Who manages the Kotak Healthcare Fund Regular Growth?

The fund managers responsible for Kotak Healthcare Fund Regular Growth are:-

Abhishek Bisen
Shibani Kurian
Dhananjay Tikariha

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Fund Overview

Fund Size

₹416 Cr

Expense Ratio

2.39%

ISIN

INF174KA1PW4

Minimum SIP

₹100

Exit Load

No Charges

Inception Date

11 Dec 2023

Risk Level

Your principal amount will be at Very High Risk